TRYNGOLZA (AUTOINJECTOR) (Olezarsen Sodium) Patent Expiration, LOE Window & CMS Spending

TRYNGOLZA (AUTOINJECTOR) (Olezarsen Sodium) by Ionis Pharmaceuticals: FDA Orange Book core substance LOE 2034-05-01, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $49,584 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIonis Pharmaceuticals
FDA Application & PathwayN218614 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2034-05-01
Last Listed Patent or Exclusivity Date2034-05-01
Orange Book Patents (*PED Extensions)13 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($49,584 intro WAC)